IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC increased its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 25.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,232 shares of the company’s stock after purchasing an additional 7,312 shares during the quarter. Intech Investment Management LLC’s holdings in IDEAYA Biosciences were worth $931,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its stake in shares of IDEAYA Biosciences by 12.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 689,073 shares of the company’s stock worth $21,830,000 after buying an additional 78,518 shares during the period. Fisher Asset Management LLC raised its position in IDEAYA Biosciences by 26.7% during the third quarter. Fisher Asset Management LLC now owns 848,909 shares of the company’s stock worth $26,893,000 after acquiring an additional 179,114 shares during the period. FMR LLC raised its position in IDEAYA Biosciences by 12.1% during the third quarter. FMR LLC now owns 12,635,653 shares of the company’s stock worth $400,297,000 after acquiring an additional 1,365,570 shares during the period. Quantbot Technologies LP acquired a new stake in shares of IDEAYA Biosciences in the third quarter valued at about $83,000. Finally, MetLife Investment Management LLC grew its position in shares of IDEAYA Biosciences by 9.6% in the third quarter. MetLife Investment Management LLC now owns 47,358 shares of the company’s stock valued at $1,500,000 after purchasing an additional 4,164 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Stephens reaffirmed an “overweight” rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Wedbush reiterated an “outperform” rating and set a $52.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $53.58.

IDEAYA Biosciences Trading Down 0.3 %

IDEAYA Biosciences stock opened at $18.39 on Monday. The company has a 50-day moving average price of $21.31 and a 200 day moving average price of $26.43. IDEAYA Biosciences, Inc. has a 12-month low of $16.95 and a 12-month high of $44.42. The stock has a market cap of $1.61 billion, a P/E ratio of -5.57 and a beta of 0.76.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.00 million. As a group, analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.